Drug profile

The FDA adverse-event record for Hyaluronate Sodium

691 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Hyaluronate Sodium. See the species affected, top reactions, and outcomes below.

691
adverse-event reports
2.6%
death-coded share
Unknown
most-reported species
101
Stopper, abnormal - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
691
Total Reports
18
Deaths Reported
2.6%
Death Rate

Active Ingredients

Hyaluronate Sodium

Administration Routes

UnknownIntra-ArticularIntravenousIntramuscularOtherOphthalmicParenteralIntraocularTopicalAuricular (Otic)

Species Affected

Unknown 422
Horse 255
Dog 10
Human 2
Cat 1
Rabbit 1

Most Affected Breeds

Unknown 480
Quarter Horse 51
Horse (unknown) 48
Warmblood (unspecified) 19
Thoroughbred 18
Warmblood - Dutch 8
Horse (other) 8
Arab 6
Paint 6
Standardbred (unspecified) 5

Most Reported Reactions

Stopper, abnormal 101
Syringe, Abnormal 96
Lameness 73
Product syringe issue 71
Uncoded sign 64
Illness NOS 46
No sign 32
Joint swelling 23
Synovitis 21
Injection site swelling 21
Containers, Leaking 21
Seal, Abnormal 20

Outcome Breakdown

Recovered/Normal
108 (44.6%)
Outcome Unknown
79 (32.6%)
Ongoing
34 (14.0%)
Died
11 (4.5%)
Euthanized
7 (2.9%)
Recovered with Sequela
3 (1.2%)

Hyaluronate Sodium Adverse Event Insights

691 reports name Hyaluronate Sodium; 18 recorded a death outcome (2.6% of reported events, not a population-level mortality rate). Active ingredient: Hyaluronate Sodium. Administration routes: Unknown, Intra-Articular, Intravenous, Intramuscular.

By species: Unknown (422 reports), Horse (255 reports), Dog (10 reports). By breed: Unknown (480), Quarter Horse (51), Horse (unknown) (48).

Leading clinical signs: Stopper, abnormal (101), Syringe, Abnormal (96), Lameness (73), Product syringe issue (71). Outcome, 242 coded reports: Recovered/Normal leads at 44.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.